17³Ô¹Ï researchers collaborating with partners to develop novel drug therapy to potentially slow ALS

Two researchers from 17³Ô¹Ï are collaborating with colleagues at the Research Institute of the McGill University Health Centre (The Institute) and Neurodyn Life Sciences Inc., a PEI-based biotechnology company, on a project to develop a novel therapy to slow, or potentially functionally stabilize, the progression of amyotrophic lateral sclerosis (ALS).

Subscribe to